---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-177791"
form_type: "8-K"
ticker: "BIIB"
cik: "0000875045"
company_name: "BIOGEN INC."
filed_at: "2022-06-21T23:59:59+00:00"
generated_at: "2026-06-25T00:39:58.509463+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Biogen EVP Chirfi Guindo to depart June 30; say-on-pay passes with 48% against

## Summary
- Chirfi Guindo, EVP Global Product Strategy, leaves June 30, 2022 for a role outside Biogen.
- All 11 director nominees elected; Richard Mulligan received 77.4M for, 38.3M against.
- PwC ratified as 2022 auditor with 123.8M votes for and 2.3M against.
- Advisory say-on-pay approved: 60.1M for, 55.3M against (47.9% against), indicating shareholder concern.
- No other material changes reported.

## SEC filing metadata
- accession: 0001193125-22-177791
- form_type: 8-K
- ticker: BIIB
- cik: 0000875045
- company_name: BIOGEN INC.
- filed_at: 2022-06-21T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875045/000119312522177791/0001193125-22-177791-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875045/000119312522177791/d367101d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-177791
- JSON: https://secwatch.observer/filing/0001193125-22-177791.json
- Plain text: https://secwatch.observer/filing/0001193125-22-177791.txt

## Key facts
- Executive change
  Chirfi Guindo departed as Executive Vice President for Global Product Strategy and Commercialization at BIOGEN INC..
  - Action: departing
  - Role: Executive Vice President for Global Product Strategy and Commercialization
  source text: On June 21, 2022, Chirfi Guindo, Executive Vice President for Global Product Strategy and Commercialization announced that he has accepted a new role outside of Biogen, Inc. (the “Company”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/875045/000119312522177791/0001193125-22-177791-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.